Table 1.
Baseline characteristics for patients in CCRT group vs. chemotherapy group
| Characteristics | CCRT (n = 55) | Chemotherapy (n = 86) | P |
|---|---|---|---|
| Sex | 0.689 | ||
| Male | 43 (78.2%) | 64(74.4%) | |
| Female | 12 (21.8%) | 22 (25.6%) | |
| Age, years | 0.862 | ||
| ≤ 60 | 32 (58.2%) | 48 (55.8%) | |
| > 60 | 23 (41.8%) | 38 (44.2%) | |
| Tumor location | 0.674 | ||
| cervical | 3 (5.5%) | 3 (3.5%) | |
| upper thoracic | 16 (29.1%) | 19 (22.1%) | |
| middle thoracic | 23 (41.8%) | 38 (44.2%) | |
| lower thoracic | 13 (23.6%) | 26 (30.2%) | |
| KPS score | 0.467 | ||
| ≥ 80 | 45 (81.8%) | 64(74.4%) | |
| < 80 | 10 (18.2%) | 22 (25.6%) | |
| T-stage | 0.816 | ||
| T1–2 | 8 (14.5%) | 15 (17.4%) | |
| T3–4 | 47 (85.5%) | 71 (82.6%) | |
| N-stage | 0.797 | ||
| N0 | 6 (10.9%) | 11 (12.8%) | |
| N+ | 49 (89.1%) | 75 (87.2%) | |
| Dysphagia score | 0.096 | ||
| 0 (asymptomatic) | 4 (7.3%) | 5 (5.8%) | |
| 1 (eat solid diet with some dysphagia) | 5 (9.1%) | 23 (26.7%) | |
| 2 (eat semisolid diet) | 28 (50.9%) | 36 (41.9%) | |
| 3 (drink liquid diet) | 13 (23.6%) | 19 (22.1%) | |
| 4 (complete dysphagia) | 5 (9.1%) | 3 (3.5%) | |
| Number of metastatic organs | 0.351 | ||
| Solitary metastasis | 41 (74.5%) | 57 (66.3%) | |
| Multiple metastasis | 14 (25.5%) | 29 (33.7%) | |
| Metastasis sites | |||
| Nonregional lymph nodes | 14 (25.5%) | 24 (27.9%) | 0.831 |
| lung | 14 (25.5%) | 16 (18.6%) | |
| liver | 17 (30.9%) | 34 (39.5%) | |
| bone | 21 (38.2%) | 36 (41.9%) | |
| others | 5 (9.1%) | 8 (9.3%) | |
| Chemotherapy regimens | |||
| PTX + DDP | 24 (43.6%) | 42 (48.8%) | 0.605 |
| 5-Fu + DDP | 31 (56.4%) | 44 (51.2%) | |
| Chemotherapy cycles | 0.585 | ||
| > 2 | 20 (36.4%) | 27 (31.4%) | |
| ≤ 2 | 35 (63.6%) | 59 (68.6%) | |
Abbreviations: CCRT concurrent chemoradiotherapy, KPS Karnofsky Performance Status, CDDP cisplatin, 5-FU 5-fluorouracil, PTX paclitaxel